Loading clinical trials...
Loading clinical trials...
Immunotherapy with CD19+CD22 CAR Redirected T-cells for High Risk/relapsed Paediatric CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Conditions
Interventions
Leukapheresis
Total Body Irradiation (TBI)
+3 more
Locations
3
United Kingdom
Great Ormond Street Hospital
London, United Kingdom
University College Hospital
London, United Kingdom
Manchester Royal Children's Hospital
Manchester, United Kingdom
Start Date
April 1, 2016
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2041
Last Updated
April 2, 2025
NCT05376111
NCT04065399
NCT07295951
NCT05453500
NCT05292664
NCT05442515
Lead Sponsor
University College, London
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions